BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.
BCRX has been the subject of several other reports. Weiss Ratings downgraded shares of BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a report on Tuesday, September 22nd. Royal Bank Of Canada downgraded shares of BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their target price for the stock from $13.00 to $11.00 in a report on Thursday, September 10th. Wedbush cut their target price on shares of BioCryst Pharmaceuticals from $18.00 to $17.00 and set an “outperform” rating for the company in a research report on Thursday. JPMorgan Chase & Co. boosted their target price on shares of BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 30th. Finally, Needham & Company LLC restated a “buy” rating and set a $16.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 8th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $20.38.
View Our Latest Stock Analysis on BCRX
BioCryst Pharmaceuticals Price Performance
Shares of BioCryst Pharmaceuticals stock opened at $7.69 on Friday. The stock has a market capitalization of $1.98 billion, a P/E ratio of -5.42 and a beta of 0.55. The stock has a 50 day moving average price of $8.46 and a two-hundred day moving average price of $8.75. BioCryst Pharmaceuticals has a 12-month low of $6.23 and a 12-month high of $11.22.
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.09 by $0.05. BioCryst Pharmaceuticals had a negative return on equity of 92.91% and a negative net margin of 37.40%. The company had revenue of $180.29 million for the quarter, compared to the consensus estimate of $165.67 million. During the same quarter last year, the company posted $0.06 earnings per share. The company’s revenue for the quarter was up 13.1% compared to the same quarter last year. Sell-side analysts anticipate that BioCryst Pharmaceuticals will post -2.26 earnings per share for the current year.
Hedge Funds Weigh In On BioCryst Pharmaceuticals
Several large investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in shares of BioCryst Pharmaceuticals during the second quarter valued at approximately $238,930,000. Jupiter Topco LLC acquired a new position in shares of BioCryst Pharmaceuticals in the second quarter valued at $95,268,000. Janus Henderson Group PLC raised its stake in shares of BioCryst Pharmaceuticals by 20.3% in the first quarter. Janus Henderson Group PLC now owns 8,908,506 shares of the biotechnology company’s stock valued at $84,854,000 after purchasing an additional 1,504,120 shares in the last quarter. Perceptive Advisors LLC lifted its position in BioCryst Pharmaceuticals by 135.1% in the first quarter. Perceptive Advisors LLC now owns 7,434,033 shares of the biotechnology company’s stock worth $70,772,000 after purchasing an additional 4,271,504 shares during the period. Finally, Aberdeen Group plc lifted its position in BioCryst Pharmaceuticals by 21.8% in the third quarter. Aberdeen Group plc now owns 6,468,726 shares of the biotechnology company’s stock worth $53,884,000 after purchasing an additional 1,157,855 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.
BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.
Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.
Recommended Stories
- Five stocks we like better than BioCryst Pharmaceuticals
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
